ACTL6A/BAF53A Rabbit mAb

Catalog No.: F4230

Application: Reactivity: Human, Monkey

Usage Information

Dilution
WB1:1000 IP1:50 CHIP1:50

Application
WB, IP, ChIP

Reactivity
Human, Monkey

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
45 kDa

Datasheet & SDS

Biological Description

Specificity
ACTL6A/BAF53A Rabbit mAb detects endogenous levels of total ACTL6A/BAF53A protein.

Clone
F6F1

Synonym(s)
atp dependent chromatin remodeling

Background
ACTL6A (Actin-like protein 6A, also known as BAF53A) is a highly conserved actin-related protein and a core subunit of the SWI/SNF (BAF) chromatin remodeling complex, which regulates nucleosome positioning and transcriptional accessibility. Structurally, ACTL6A resembles actin in its ATP-binding fold but functions primarily in chromatin remodeling rather than cytoskeletal dynamics. It is predominantly expressed in stem cells, progenitor cells, neuronal precursors, and various epithelial tissues, where it maintains proliferative capacity and inhibits terminal differentiation. Functionally, ACTL6A promotes transcriptional programs associated with stemness, proliferation, epithelial–mesenchymal transition (EMT), and oncogenesis, often through interactions with transcription factors such as SOX2, c-Myc, p63, and signaling pathways including Notch and Hippo-YAP. Overexpression or amplification of ACTL6A has been reported in multiple cancers (e.g., hepatocellular carcinoma, ovarian cancer, head and neck squamous cell carcinoma, glioma, and cervical cancer), where it enhances tumor cell growth, invasion, therapy resistance, and poor prognosis, making it a critical oncogenic driver and potential therapeutic target.

Background

ACTL6A (Actin-like protein 6A, also known as BAF53A) is a highly conserved actin-related protein and a core subunit of the SWI/SNF (BAF) chromatin remodeling complex, which regulates nucleosome positioning and transcriptional accessibility. Structurally, ACTL6A resembles actin in its ATP-binding fold but functions primarily in chromatin remodeling rather than cytoskeletal dynamics. It is predominantly expressed in stem cells, progenitor cells, neuronal precursors, and various epithelial tissues, where it maintains proliferative capacity and inhibits terminal differentiation. Functionally, ACTL6A promotes transcriptional programs associated with stemness, proliferation, epithelial–mesenchymal transition (EMT), and oncogenesis, often through interactions with transcription factors such as SOX2, c-Myc, p63, and signaling pathways including Notch and Hippo-YAP. Overexpression or amplification of ACTL6A has been reported in multiple cancers (e.g., hepatocellular carcinoma, ovarian cancer, head and neck squamous cell carcinoma, glioma, and cervical cancer), where it enhances tumor cell growth, invasion, therapy resistance, and poor prognosis, making it a critical oncogenic driver and potential therapeutic target.

References
https://pubmed.ncbi.nlm.nih.gov/34395295/ https://pubmed.ncbi.nlm.nih.gov/30348114/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%